Molecular Devices Introduces SpectraMax(R) M5 Multi-Detection Microplate Reader System

Molecular Devices Introduces SpectraMax(R) M5 Multi-Detection
Microplate Reader System 


SUNNYVALE, Calif., Oct. 25  /PRNewswire-FirstCall/ -- Molecular Devices
Corporation (NASDAQ:MDCC) today announced the introduction of SpectraMax(R) M5,
a five-mode multi-detection microplate reader system, and the latest addition
to the company's popular SpectraMax product line. The system has primary
applications for fluorescence intensity, absorbance, luminescence,
Time-Resolved Fluorescence (TRF) and Fluorescence Polarization (FP) assays, and
will debut today at Neuroscience 2004 in San Diego, California. The SpectraMax
M5 will allow life science and drug discovery researchers to increase their
productivity by giving them multiple detection modes in one powerful, compact
instrument.

The SpectraMax M5 features a triple-mode cuvette port and a single-read command
capability for experiments requiring multiple detection parameters. The system
also gives users the flexibility to choose wavelengths between 200 nm and 1000
nm. The SpectraMax M5 uses standard microplates to read endpoint, kinetic,
spectrum, multi-wavelength and well-area scanning. For life sciences research,
the system is well suited for ELISA, nucleic acid, protein quantitation,
enzymatic, cell viability and proliferation assays. Kinase, reporter gene, FRET
and other homogeneous and heterogeneous assays can also be run.

Commenting on the launch, Stephen J. Oldfield, Ph.D., Molecular Devices' Vice
President of Worldwide Marketing, stated, "The SpectraMax M5 has optical
performance which is comparable to our dedicated, top-of-the-line readers for
all five of its primary detection modes. With its broad assay capability, this
system can be used as a research tool to optimize assays in early ADME or
quality control, or used as a screening instrument." He further stated, "When
the SpectraMax M5 is integrated with our SynchroMax(TM) ET plate handling
robot, up to 320 plates can be run without interruption, with multiple assay
parameters on each plate."

SpectraMax M5 utilizes SoftMax(R) Pro Enterprise software, the industry-
leading data acquisition and analysis software with FDA 21 CFR Part 11
compliance tools.

Molecular Devices Corporation is a leading supplier of high-performance
bioanalytical measurement systems that accelerate and improve drug discovery
and other life sciences research.  The Company's systems and consumables enable
pharmaceutical and biotechnology companies to leverage advances in genomics,
proteomics and combinatorial chemistry by facilitating the high- throughput and
cost-effective identification and evaluation of drug candidates.  The Company's
solutions are based on its advanced core technologies that integrate its
expertise in engineering, molecular and cell biology and chemistry.  Molecular
Devices enables its customers to improve research productivity and
effectiveness, which ultimately accelerates the complex process of discovering
and developing new drugs.

This press release contains "forward-looking" statements, including statements
related to the prospects for or potential customer use of the SpectraMax(R) M5.
Any statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "will," and similar expressions
are intended to identify forward-looking statements. There are a number of
important factors that could cause the results of Molecular Devices Corporation
to differ materially from those indicated by these forward-looking statements,
including, among others, risks related to the development of new products and
other risks detailed from time to time in the Company's SEC reports, including
its Annual Report on Form 10-K for the year ended December 31, 2003, as
amended, and its Quarterly Report on Form 10-Q for the quarter ended June 30,
2004.  Molecular Devices Corporation does not undertake any obligation to
update forward-looking statements. 

DATASOURCE: Molecular Devices Corporation



CONTACT:  Tim Harkness of Molecular Devices Corporation, [phone]



Web site:  http://www.moleculardevices.com/ 

Copyright